Industry / United Kingdom
GSK To Target Emerging Markets
May 2008 | Company News AlertLike all of its peers, UK-based multinational GlaxoSmithKline (GSK) is adapting to the pharmaceutical industry's new and challenging operating paradigm. While the demand for innovative medicines continues to grow worldwide, negative pressures such as cost containment, regulatory demands and generic competition are constantly eroding bottom lines. Anticipating the so-called 'patent-cliff' in 2011, GSK's CEO-designate Andrew Witty has revealed a new strategy that places emphasis on emerging markets, especially those in
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
